Results 101 to 110 of about 13,103,023 (178)

Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?

open access: yesJournal of Hepatology, 2015
Currently available antiviral treatment for chronic hepatitis B (CHB) infection can be divided into two classes of therapeutic agents: pegylated interferon alpha (PegIFN) and nucleos(t)ide analogues (NAs). The advantages of PegIFN include a finite course of treatment, the absence of drug resistance, and an opportunity to obtain a durable post-treatment
openaire   +2 more sources

Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B

open access: yesAnnals of Medicine
Background Chronic hepatitis B (CHB) is a major cause of hepatocellular carcinoma (HCC). In patients receiving CHB treatment, coexistence of steatotic liver disease (SLD) and cardiometabolic risk factors (CMRFs) markedly influence HCC risk.
Hung-Wei Wang   +5 more
doaj   +1 more source

Discontinuation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B infection: Is it possible?

open access: yes, 2023
Background and aims: Chronic hepatitis B infection is a global public health challenge, associated with significant morbidity and mortality. Nucleos(t)ide analogue treatment is crucial for disease management, but the optimal duration of treatment is ...
GOMES DIAS, J.
core  

Dynamic shifts in trophoblast nucleos(t)ide metabolism, transport, and adenosine signaling during gestation and preterm birth

open access: yes
Nucleos(t)ides are essential for DNA/RNA synthesis, energy metabolism, and signaling, yet their roles in placental development remain poorly understood.
Antonin Libra   +10 more
core   +1 more source

Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued

open access: yesInfection and Drug Resistance, 2022
Guichan Liao, Ziying Liu, Muye Xia, Hongjie Chen, Houji Wu, Bing Li, Tao Yu, Shaohang Cai, Xiaoyong Zhang, Jie Peng State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious ...
Liao G   +9 more
doaj  

Changes in renal function in CHB patients with Peg-IFN combined with nucleos(t)ide analogs

open access: yes
Abstract Background There is limited research comparing the renal safety of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) when used with pegylated interferon (pegIFN) in patients with chronic hepatitis B (CHB). Here, renal function changes in CHB patients were compared between treated with pegyIFN combined with ETV or TDF.
Jinhua Zhao   +4 more
openaire   +1 more source

Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual

open access: yes
Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley   +1 more source

Impact of nucleos(t)ide analogue therapy on the incidence of Alzheimer’s disease in patients with chronic hepatitis B virus infection

open access: yesAlzheimer’s Research & Therapy
Background Long-term therapy with nucleos(t)ide analogs (NUCs) is inevitable for chronic hepatitis B (CHB) patients. However, how NUC therapy on the developing Alzheimer’s disease (AD) in these patients remains controversial.
Jihye Lim   +4 more
doaj   +1 more source

Liver dysfunction and clinical outcomes of unvaccinated COVID-19 patients with and without chronic hepatitis B

open access: yesJournal of Microbiology, Immunology and Infection
Background: Liver dysfunction is common during coronavirus disease 2019 (COVID-19), while its clinical impact and association with chronic hepatitis B (CHB) remain uncertain.
Hao-Che Chang   +6 more
doaj   +1 more source

Nucleos(t)ide Analog Treatment Discontinuation in Chronic Hepatitis B Virus Infection: A Systematic Literature Review

open access: yesGastro Hep Advances
The aim of this systematic literature review (SLR) was to examine outcomes and associated predictors following nucleos(t)ide analog (NA) treatment cessation in adult patients with chronic hepatitis B virus infection.The SLR was conducted according to PRISMA methodology.
Robert Gish   +8 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy